O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al
and foam cell formation and endothelial cell apoptosis, which reduces the atherosclerotic plaques necrotic core
Event Phase 2 Rate (12 mg group) Phase 2 Rate (Placebo) Nausea 45.8% 11.6% Diarrhea 33.3% 9.3% Vomiting 22.2% 2.3% Constipation 16.7% 7.0% Decreased appetite 22.2% 2.3% The nausea incidence at the highest dose a nausea percentage of roughly 46% makes it the single most reported adverse event in retatrutide clinical trials 2026 data
Vision Complications NAION: Though not as common, theres concern over Ozempics connection to vision loss via Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), due to possible impacts on blood flow to the optic nerve
Fischer, D
In recent years, GLP-1 approvals have expanded beyond blood sugar management and weight loss to include other organs, like the heart, kidneys, and liver